Company intelligence / Profile preview
NapaJen Pharma
Seattle, Washington, United Statesnapajen.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
NJA-730, the lead program, is in clinical development for prevention of acute immune diseases (Graft vs Host Disease) associated with bone marrow transplants; other programs are in preclinical stages in immuno-oncology, vaccine adjuvants, and autoimmunity. No published clinical results yet.
- Therapeutic areas
- ImmunologyOncology
- Modalities
- OligonucleotideSmall interfering RNARNA therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Not specified in search results; company positions as a “partner-of-choice” for pharma/biotech seeking oligonucleotide drug delivery
Beyond the preview
Go deeper on NapaJen Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NapaJen Pharma.